Efforts will be made to extend accrual to a representative population, but in this preliminary study, a balance must be struck between patient safety considerations and limitations on the number of individuals exposed to potentially toxic and/or ineffective treatments on one hand and the need to explore ethnic aspects of clinical research on the other hand. If differences in outcome that correlate with ethnic identity 57 Short Title: Enzalutamide Vaccine in mCRPC Version Date: 03/29/2022 are noted, accrual may be expanded or a follow-up study may be written to investigate those differences more fully. Women are not eligible for this protocol as this disease occurs only in men. 11.1.2 Justification for Exclusions Due to impaired cellular immunity with the concomitant increased risk of serious side effects from vaccinations with infectious agents, the Centers for Disease Control and Prevention recommends that HIV infected patients be excluded, in addition, patients with chronic hepatitis infection, including B and C, because of potential immune impairment will be excluded. 11.2 PARTICIPATION OF C HILDREN Because no dosing or adverse event data are currently available on the use of PSA-TRICOM Vaccine or enzalutamide in patients <18 years of age, children are excluded from this study, but may be eligible for future pediatric trials. 11.3 PARTICIPATION OF S UBJECTS UNABLE TO GIVE C ONSENT Adults unable to give consent are excluded from enrolling in the protocol.